• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B3 filed by Check-Cap Ltd.

    2/24/26 9:05:00 AM ET
    $MBAI
    Medical Electronics
    Health Care
    Get the next $MBAI alert in real time by email
    424B3 1 ea0278117-424b3_checkcap.htm PROSPECTUS SUPPLEMENT

    PROSPECTUS SUPPLEMENT NO. 1

    (TO PROSPECTUS DATED FEBRUARY 23, 2026)

      Filed pursuant to Rule 424(b)(3)
    Registration No. 333-293109

     

    Up to 2,267,857 Ordinary Shares

     

     

     

    Check-Cap Ltd.

     

    This is a supplement (the “Prospectus Supplement”) to the prospectus, dated February 23, 2026 (as supplemented or amended from time to time, the “Prospectus”) of Check-Cap Ltd. (the “Company”), which forms a part of the Company’s Registration Statement on Form F-1 (Registration No. 333-293109), as amended from time to time.

     

    This Prospectus Supplement is being filed to update and supplement the information included in the Prospectus with the information contained in the Company’s Report on Form 6-K, furnished to the U.S. Securities and Exchange Commission (the “Commission”) on February 24, 2026 (“Form 6-K”). Accordingly, the Form 6-K is attached to this Prospectus Supplement.

     

    This Prospectus Supplement should be read in conjunction with, and delivered with, the Prospectus and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained in the Prospectus. The Prospectus Supplement included website addresses solely as inactive textual references. The information contained on those websites is specifically not incorporated by reference into this Prospectus Supplement.

     

    This Prospectus Supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

     

    Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6 of the Prospectus and “Item 3. — Key Information — D. Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024 for a discussion of information that should be considered in connection with an investment in our securities.

     

    Neither the Commission nor any state or other foreign securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    The date of this prospectus supplement is February 24, 2026.

     

     

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of February 2026

     

    Commission File Number: 001-36848

     

    Check-Cap Ltd.

    (Exact Name of Registrant as Specified in Charter)

     

    Abba Hushi Avenue

    P.O. Box 1271

    Isfiya, 30090 Mount Carmel, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

    1

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-262401) and Form S-8 (File No. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

     On February 24, 2026, Check-Cap Ltd. (the “Check-Cap”) announced that MBody AI Corp. (“MBody AI”) has submitted its Nasdaq listing application, representing a significant regulatory milestone toward closing the previously announced merger between Check-Cap and MBody AI.

     

    A copy of the press release announcing this development is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Exhibit No.   Description
    99.1   Press Release.

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CHECK-CAP LTD.
      (Registrant)
         
    Date: February 24, 2026 By: /s/ David Lontini
      Name: David Lontini
      Title: Interim Chief Executive Officer

     

    3

     

     

    Exhibit 99.1

     

    MBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close

     

    Proposed Nasdaq-listed AI company achieves key regulatory milestone as merger with Check-Cap targets first half of 2026; $30M growth facility available

     

    ISFIYA, Israel, February 24, 2026 (GLOBE NEWSWIRE) — Check-Cap Ltd. (NASDAQ: MBAI) (“Check-Cap” or the “Company”), a Nasdaq-listed company, today announced that MBody AI Corp. (“MBody AI”) has submitted its Nasdaq listing application, representing a significant regulatory milestone toward closing the previously announced merger between Check-Cap and MBody AI. The submission of the application further advances the prospective combined company toward its anticipated Nasdaq Capital Markets (“Nasdaq”) listing, targeted for the first half of 2026, subject to customary closing conditions.

     

     

     

    The Nasdaq application submission follows a series of significant milestones achieved in recent months, including the Company’s regaining compliance with Nasdaq continued listing requirements, the filing of a Form F-1 Registration Statement in connection with the equity line of credit facility with ARC Group International Inc., and the furnishing of MBody AI’s audited financial statements as of December 31, 2024 and for the period from October 7, 2024 (date of formation) to December 31, 2024, and as of June 30, 2025 and for the six months then ended, each of which has contributed to accelerating the trajectory toward closing.

     

    “The submission of our Nasdaq listing application is a major step forward in bringing MBody AI to the public markets,” said John Fowler, Chief Executive Officer of MBody AI. “This milestone, combined with our completed audits and the Company’s regaining Nasdaq compliance, reflects the tremendous progress we have made across every dimension of this process. The physical AI opportunity is real, it is scaling now, and MBody AI is positioned at the center of it. We look forward to welcoming public-market investors into that story.”

     

    “We are excited for the future prospect of the combined company. We remain on track to close in the first half of 2026, and we are more energized than ever about what comes next,” said David Lontini, Chairman of the Board and Interim Chief Executive Officer of Check-Cap.

     

     

     

     

    About Check-Cap Ltd.

     

    Check-Cap Ltd. (NASDAQ: MBAI) is a technology company executing a strategic transformation through its shareholder-approved merger with MBody AI. Upon completion, Check-Cap expects to become a publicly traded leader in embodied artificial intelligence, delivering enterprise-grade AI orchestration for robotic systems across hospitality, healthcare, logistics, and data center operations.

     

    About MBody AI Corp.

     

    MBody AI is an embodied artificial intelligence company building the autonomous workforce of the future. Its proprietary, hardware-agnostic MBody AI Orchestrator™ platform delivers real-time data intelligence and AI-driven performance insights for robotic fleets, with capabilities spanning deployment optimization, predictive maintenance, and full-fleet coordination. MBody AI serves Fortune 500 enterprises and blue-chip customers across multiple industry verticals. For more information, visit www.mbody.ai.

     

    Investor Information

     

    Learn more about MBody AI’s growth trajectory at investors.mbody.ai

     

    Forward-Looking Statements

     

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, which include, among others, statements regarding the completion and timing of the merger with MBody AI, the anticipated Nasdaq listing and commencement of trading, the Company’s ability to maintain continued compliance with Nasdaq listing requirements, the expected benefits of the merger, MBody AI’s technology roadmap and commercial scaling, the Company’s beliefs about market and technology trends, the anticipated growth of the embodied AI market, the future operations and positioning of the combined company, the anticipated use or non-use of the equity line of credit facility with ARC Group International Inc., and the expected timeline for closing the merger. These forward-looking statements are based on the Company’s current intentions, beliefs, and expectations regarding future events. Actual results may differ materially due to risks and uncertainties including, but not limited to, the satisfaction of closing conditions, the ability to complete the merger on the anticipated timeline or at all, the ability to receive Nasdaq approval and commence trading, integration risks, customer concentration risks, market conditions, and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

     

    Media Contact

    MBody AI Corp.

    Email: [email protected]

    Phone: (725) 666-1750

     

    Investor Relations

    MZ Group North America
    Shannon Devine/ Jamie Kirchen
    [email protected]

     

     

     

     

     

    Get the next $MBAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MBAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close

    ISFIYA, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:MBAI) ("Check-Cap" or the "Company"), a Nasdaq-listed company, today announced that MBody AI Corp. ("MBody AI") has submitted its Nasdaq listing application, representing a significant regulatory milestone toward closing the previously announced merger between Check-Cap and MBody AI. The submission of the application further advances the prospective combined company toward its anticipated Nasdaq Capital Markets ("Nasdaq") listing, targeted for the first half of 2026, subject to customary closing conditions. The Nasdaq application submission follows a series of significant milestones achieved in recent months, i

    2/24/26 8:35:00 AM ET
    $MBAI
    Medical Electronics
    Health Care

    Check-Cap Advances MBody AI Merger with F-1 Filing and MBody AI Audited Financials

    ISFIYA, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:MBAI) ("Check-Cap" or the "Company") today announced key regulatory milestones supporting the completion of its previously announced merger with MBody AI Corp. ("MBody AI"), the filing of a Form F-1 Registration Statement and the furnishing of MBody AI's audited financial statements on Form 6-K. These filings follow the Company's return to compliance with Nasdaq continued listing requirements and represent significant steps toward closing the merger in the first half of 2026. F-1 Filing Supports Strategic Capital Flexibility The Form F-1 registers shares in connection with Check-Cap's previously announced equity

    2/2/26 8:35:00 AM ET
    $MBAI
    Medical Electronics
    Health Care

    Check-Cap Clears Key Nasdaq Requirement, Advancing MBody AI Merger Toward Completion

    ISFIYA, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:MBAI) ("Check-Cap" or the "Company") today announced that it has received written confirmation from the Nasdaq Listing Qualifications Department that the Company has regained compliance with Nasdaq's minimum shareholders' equity requirements pursuant to Nasdaq Listing Rule 5550(b). This confirmation clears a key regulatory requirement and represents a significant positive milestone as Check-Cap advances toward completion of its previously announced, shareholder-approved merger with MBody AI. The merger is expected to transform Check-Cap into a publicly traded leader in embodied artificial intelligence, subject to c

    1/26/26 9:50:00 AM ET
    $MBAI
    Medical Electronics
    Health Care

    $MBAI
    SEC Filings

    View All

    SEC Form 424B3 filed by Check-Cap Ltd.

    424B3 - Check-Cap Ltd (0001610590) (Filer)

    2/24/26 9:05:00 AM ET
    $MBAI
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    2/24/26 9:02:58 AM ET
    $MBAI
    Medical Electronics
    Health Care

    SEC Form 424B3 filed by Check-Cap Ltd.

    424B3 - Check-Cap Ltd (0001610590) (Filer)

    2/23/26 5:00:34 PM ET
    $MBAI
    Medical Electronics
    Health Care